Skip to main content

Table 2 Intercenter characteristics a

From: Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

Characteristics

Center 1 (N = 82)

Center 2 (n = 124)

Center 3 (n = 161)

P -value b

AD patients

    
 

Number of subjects (%)

37 (45.1)

73 (58.9)

50 (31.1)

<0.001

 

Age (yr), mean (SD)

68.9 (8.6)

67.0 (9.5)

68.5 (10.7)

0.54

 

Women, n (%)

27 (73.0)

39 (53.4)

31 (62.0)

0.14

 

MMSE, mean (SD)

18.6 (6.5)

19.5 (6.3)

22.8 (4.9)

0.003

 

CSF biomarkers, pg/ml, mean (SD)

    
  

Total tau

599.5 (281.2)

774.2 (370.7)

539.6 (315.2)

<0.001

  

p-tau181

79.4 (24.4)

101.5 (42.2)

80.0 (39.2)

0.002

  

Aβ42

656.9 (257.1)

603.2 (245.4)

772.5 (363.5)

0.008

  

Aβ40

16,229.7 (6,252.8)

13,426.8 (5,250.9)

20,814.3 (12,114.6)

<0.001

  

Aβ 42/40

0.044 (0.018)

0.049 (0.021)

0.045 (0.025)

0.39

Non-AD patients

    
 

Number of subjects (%)

45 (54.9)

51 (41.1)

111 (68.9)

<0.001

 

Age (yr), mean (SD)

63.3 (10.7)

64.4 (10.6)

65.0 (11.8)

0.70

 

Women, n (%)

17 (37.8)

20 (40.0)

56 (50.4)

0.25

 

MMSE, mean (SD)

23.7 (4.9)

20.9 (6.1)

24.7 (5.3)

<0.001

 

CSF biomarkers (pg/ml), mean (SD)

    
  

Total tau

201.5 (64.0)

283.8 (150.5)

308.6 (248.6)

0.01

  

p-tau181

40.4 (12.8)

46.2 (15.8)

40.8 (19.7)

0.14

  

Aβ42

984.3 (253.6)

987.0 (344.7)

1,039.3 (343.3)

0.50

  

Aβ40

12,219.5 (4,775.2)

11,161.0 (4,955.5)

17307.2 (9,952.7)

<0.001

  

Aβ 42/40

0.087 (0.024)

0.098 (0.041)

0.077 (0.066)

0.06

  1. aAβ, Amyloid-beta; AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; MMSE, Mini Mental State Examination; p-tau181, tau phosphorylated at threonine 181; SD, Standard deviation. bBy χ2 test or analysis of variance.